ISSN (Print): 1871-5303
ISSN (Online): 2212-3873
Volume 21, 12 Issues, 2021
Download PDF Flyer
Open Access Funding
Promote Your Article
ISSN (Print): 1871-5303
ISSN (Online): 2212-3873
Aims & Scope
BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Cambridge Scientific Abstracts (CSA)/ProQuest, Chemical Abstracts Service/SciFinder, ChemWeb, CNKI Scholar, Dimensions, EBSCO, EMBASE/Excerpta Medica, ERA 2018, Genamics, JournalSeek, Google Scholar, InCites, J-Gate, JournalTOCs, MediaFinder®-Standard Periodical Directory, MEDLINE/PubMed/Index Medicus, Norwegian Register, PubsHub, QOAM
Science Citation Index Expanded™ (SciSearch®), Scilit, Scopus, Suweco CZ, TOC Premier, and Ulrich's Periodicals Directory.
Ranking and Category:
Submit Abstracts / Manuscripts Online
Animated Abstract Submission
View Full Editorial Board
5 - Year: 3.037
Fabricating and Stating False Information
Self Archiving Policies
Peer Review Workflow
Free Copies Online
Open Access Articles
Most Cited Articles
Advertise With Us
Most Accessed Articles
Most Popular Articles
Special Issue Submission
MicroRNAs in colon and rectal cancer
Guest Editor(s):Surajit Pathak, Antara Banerjee
Metabolic and Hormonal Alterations in neuro-psychiatric disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets, Volume 18, Number 4
Guest Editor(s): Omar Cauli
"EMID-DT is a prestigious journal with a multidisciplinary coverage. Its aim is to provide cutting- edge information to readers working in different field of research ranging from immune endocrine to metabolic disorders."
Max Planck Institude, Germany
Thank you for your email. Our experience of publishing with Endocrine, Metabolic and Immune Disorders - Drug Targets has been pleasant and smooth. The reports from peer reviewers arrived within a reasonable time frame and their comments were most constructive and helpful. The editors are meticulous and responsive. We hope to publish with your esteemed journal again in the near future.
35 Abstract Ahead of Print are available electronically
98 Articles Ahead of Print are available electronically
The immune system plays a central role in health and disease conditions, including cancer and has become very important
in cancer patients because cancer and its treatments, including chemotherapy, radiotherapy, high dose of steroids, and targeted
cancer drugs for long term use, weaken the immune system that plays a critical role in fight against cancer. Inflammation is
critical in tumor progression and infiltrated immune cells such as macrophages, basophils, eosinophils, and dendritic cells govern
the inflammatory responses in the tumor microenvironment with fibro inflammation. Immunotherapy, including immunosurveillance
and immunoediting, has been used for the past few years for the treatment of cancer. These techniques are based
on protection against tumor proliferation as well as the identification of targets with the help of vaccines and antibodies for immune
recognition of different cancers. Anti-inflammatory agents have the potential to prevent cancer but compromise the host
immune system. Various other cellular therapies are also involved in the removal of immune cells from the tumor or blood as
well. The immune-modulating role of cytokines produced by the tumor cells allows the cytokines to be used as drugs for activating/
modulating the immune response. The purpose of this special issue is to summarize the beneficial and adverse effects of
inflammation in cancer and tumorigenesis, along with recent advances in cancer immunotherapy, immunosurveillance, drug
targeting, and delivery systems in cancer therapy.
Circulating biomarkers are currently an exciting topic in research which holds a great promise in diagnosis, patient management,
and therapeutic target in gliomas. Various strategies have been developed to understand the role of miRNAs in therapies.
However, it is very difficult to deliver the miRNAs into the central nervous system. The diagnostic and prognostic efficacy
of miRNAs in glioma, however, remains unclear. Numerous small-scale studies of glioma identified promising circulating
miRNAs that require further assessment and validation before their application in clinical practice.
Prostate cancer is a most common multifactorial disease which includes somatic, genetic, and epigenetic changes, resulting
in the inactivation of tumor-suppressor genes and activation of oncogenes. Chronic inflammation also plays a major role in the
onset and progression of human cancer, via modifications in the tumor microenvironment by initiating epithelial-mesenchymal
transition and remodeling the extracellular matrix. Genome-wide DNA methylation marks and chromatin protein marks are
being systematically applied to study prostate cancer cases, which provide new insights into prostate cancer cell phenotypes and
innumerable new molecular biomarkers for prostate cancer. Complete knowledge of the mechanisms associated with genetics,
epigenetics, and inflammation in prostate cancer may provide tangible benefits from both the scientific and clinical aspects related
to the introduction of new diagnostic and therapeutic methods.
The human-associated microbiome is of considerable importance for its role in human health, especially in diseases like
cancer. The role of the microbiome in its initiation, progression, and therapy is still poorly understood. There are various roles
of the microbiome in cancer such as modulating cancer progression, and therapeutic opportunities.The challenges associated
with microbiome including microbiota transplantation and probiotics, are discussed.
Prebiotics are non-digestible oligosaccharides that consist of different monosaccharide units with different linkages and
degrees of polymerization. The commonly available prebiotics are fructooligosaccharides (FOS), transgalactooligosaccharides
(TOS or Trans GOS), xylooligosaccharides (XOS), maltooligosaccharides (MOS), and isomaltooligosaccharides (IMO), which
mainly consist of glucose, galactose, xylose, and fructose as building units. The functions of prebiotics beneficial for human
health include, mineral absorption, better immune response, increased resistance to bacterial infection, improved lipid metabolism,
possible protection against cancer, relief from poor digestion of lactose, and reduction in the risk of diseases such as intestinal
disease, non-insulin-dependent diabetes, obesity, and allergy. Hence prebiotics are rapidly moving to the mainstream as
therapeutic agents that activate immune responses to control cancer progression.
Nanotechnology has paved the way to develop new and novel therapeutic and diagnostic approaches to treat cancer. Pancreatic
cancer is the fifth leading cause of cancer deaths in the USA alone. The delayed prognosis with fibrillar capsule development
around the tumor contributes to drug resistance and high mortality of 85%. Recent advances in the treatment of pancreatic
cancer have improved the survival percentage relatively. The diagnosis of pancreatic cancer has improved with the identification
of novel markers in the early stages of cancer. The developments in pancreatic cancer treatment and imaging are discussed.
Scientific research continues to develop more efficacious drugs to treat and cure cancer. Important anticancer synthetic
compounds highlight the plant-derived polyphenolic compounds/extracts and their therapeutic potential in treating different
types of cancers. Since the one-drug one-target approach fails to yield the desired therapeutic effect, a combination therapy
where the synergistic effect on multiple targets is possible has gained significance. Anticancer polyphenolic compounds and
synthetic compounds are discussed. Systematic research studies for screening combinations of plant phenolic compounds with
potential chemotherapeutic drugs/formulations, their synergistic effects, and mechanisms of action could greatly contribute to
the scientific mission of exploring efficacious drugs to save the human race from the dreadful disease, cancer.
Colorectal cancer (CRC), a heterogeneous malignancy, has developed into the third extensively spread cancer with an increased
diagnosis rate every year. Various factors including family history, altered diet, tobacco smoking, adenomatous polyps,
and inflammatory bowel disease (IBD) has augmented the risk of tumorigenesis. The increased CRC cases and associated
symptoms have elevated the requirement of novel biomarker identification for early diagnosis and treatment of CRC.
IDB is increasingly associated with Ulcerative colitis and CRC as a range of biomarkers overlap between the conditions.
This includes the ectopic production of microRNAs (miRNAs) in various affected tissues and vascular systems. These small
non-coding RNAs undergo base pairing with 3' untranslated regions of mRNAs of specific genes, hence modulating gene expression
by post-transcriptional regulation, making them candidate biomarkers.
CRC research in the past decade has targeted miRNA as an inducer of multiple cancers, but its importance in CRC has not
reached its full scope. Zhu et al.  have highlighted the association of miRNA in colon cancer by performing both in vitro and
in vivo experiments in the identification of cancer hub genes and key miRNAs in CRC patients. Similarly, Feng et al.  have
summarised a range of miRNA interactions in different target genes and their level of expression in CRC. Hence, providing a
repository of miRNA targets for previously recognized CRC oncogenes. As described by He et al.  miRNA molecular biomarkers
act as a rheostat in cancer by targeting specific genes, including AEG-1 leading to either up or down-regulation of the
Inflammation, as a recurrent characteristic of CRC cells, has highlighted the involvement of CRC subtype colitis-associated
cancer (CAC) and in the cancer diagnosis. Thereby accelerating the significance of colitis and colitis-related molecular mediators
as CRC diagnostic tool. Further evidence of miRNA influences in CRC, established through CAC has been demonstrated
by Shi et al. . They proved an elevated miRNA-21 level in mouse CRC, human CAC, and CRC tumor samples. Further,
knockout of miRNA -21 in mice leads to a decrease in pro-inflammatory and carcinogenic cytokines. Loss of this miRNA triggered
apoptosis in the mice tumor cells by repressing STAT3 and Bcl-2 expression. Confirmation of miRNA 21 in CRC advancement
has also been presented by Mimaet al. [5, 6], elucidating the role of prostaglandin-endoperoxide synthase 2 induced
inflammatory response leading to increased expression of miRNA 21. The research sheds light on the effect of the inflammatory
tumor microenvironment in CRC tumor metastasis.
The importance of non-coding RNAs like miRNA, reviewed in detail by Jothimani et al. explains the different roles played
by miRNA, including cell fate determination, apoptosis, proliferation, inflammation, and several aspects associated with CRC
development. Despite the mounting evidence of miRNA involvement, the biological mechanism behind the miRNA and
mRNA interaction in CRC is poorly understood. These potential therapeutic targets serve a novel strategy for earlier CRC detection
This issue is focused on the latest developments in management of endocrine and metabolic disorders. By bringing together
recent work in this area, we aim to provide an outline of the potential exploitation avenues open to endocrinologists. This issue
will serve a medium for the dissemination of information on how to initiate or manage many existing and/or emerging treatments
used in endocrine and metabolic conditions.
Endocrine disorders involve body's over or under-production of certain hormones, while metabolic disorders affect the
body's ability to process certain nutrients and vitamins. Metabolism and endocrinology trigger every aspect of our lives, from
the functioning of a single cell through our ability to run a marathon. Therefore, it is not surprising that defects in endocrine or
metabolic function underlie many common human diseases, including endocrinology cancer, cardiovascular disease, pediatric
endocrinology (disorders of the endocrine glands), diabetes and neurodegenerative disorders. These disorders pose a serious
public health challenges for both the developed and developing world as according to recent worldwide estimates, 1.7 billion
people are classified as either overweight or obese, and more than 500 million have either pre-diabetes or type 2 diabetes mellitus.
Many other endocrine and metabolic conditions are also very prevalent and include postmenopausal states, thyroid disorders,
metabolic bone diseases, and type 1 diabetes mellitus (T1DM).
This special issue focuses on all areas of endocrinology and metabolism. It lays emphasis on the use of pharmacogenomics
and personalised medicine for diabetes management, discusses the use of MicroRNAs as biomarker for breast cancer, improvement:
Insights and Perspectives on menopausal remediation and Quality Of Life (QoL). It brings insights into transdermal
drug delivery approaches for redressal of osteoporosis and explains the significance, challenges and the ways and means in
regulating endocrine disruptors. It also stresses about the role and developments of natural products for therapeutic and prophylaxis
of endocrine and metabolic disorders like impact on wound healing and tissue repair properties of chitosan, natural products
for obesity, molecular and immunological mechanisms of bioflavonoids e.g. rutin and bibliometrics and visualization
analysis of animal model for parkinson's disease.
Therapeutic advances in endocrinology and metabolism includes developments in both the existing (i.e. drug, surgery, radiotherapy,
and biotherapy) and investigational treatment modalities (e.g. gene therapy, nanotechnology and regenerative medicine).
One of the future goals of endocrine and metabolic clinical care is to make chronic diseases curable by having a clear
understanding of the new trends in research and technology.
Frailty and cognitive impairment are common debilitating conditions associated with poor quality of life and premature
mortality not only during aging but also in younger individuals with chronic disorders. Several immune alterations are found in
individuals who developed a state of frailty and cognitive impairment. The knowledge of these alterations may offer the possibility
to evaluate new pharmacological and nonpharmacological interventions to improve the health status leading to an improvement
in patients' lives and their environment. The special issue wishes to describe recent progress in the discovery, validation,
and standardization of molecular biomarkers and clinical interventions aimed to modulate the immune system in individuals
with frailty and cognitive impairment. The thematic issue wished to shed new light in this exciting and insightful field
of research from a multidisciplinary perspective. This issue of Endocrine, Metabolic & Immune Disorders Drug Targets, ‘‘Immune
alterations in frailty syndrome and cognitive impairment” reflects the interplay between different health sciences at the
leading edge of this growing research field which intensively suggests new opportunities for improving the care or to prevent
adverse outcomes. In the special issue, readership will find relevant researches carried out by several health care professionals
and researchers with extensive knowledge in the clinical setting and intended to address new issues of interest of specific importance
to research and clinical practise. Gimeno-Mallench et al.  reviewed the importance and the characteristic of a balanced
diet for older individuals in order to ensure proper immune and metabolic functions. Particularly, the authors focused on
increasing protein intake for elderly people as long as there is no kidney damage. This increase could help fight the loss of
muscle mass (sarcopenia) associated with age. Additionally, vitamin and mineral intakes are often insufficient in their diets.
Therefore, diet for older individuals should be adapted not only to their age but also to the pathologies associated with aging.
Through these measures, we can reduce the prevalence of comorbidity and thereby increase the health span. Therefore, both
physical and nutritional interventions, including functional foods and nutraceuticals, should be taken into account. Jordá et al.
 reviewed the role of microglia cells and astrocytes as key inflammatory cells associated with Alzheimer's disease producing
several inflammatory mediators, such as cytokines and chemokines. Chemokines and their receptors are low molecular weight
able to control the migration and residence of immune cells. In pathological conditions, such as Alzheimer's disease, chemokines
contribute to the inflammatory response by recruiting T cells and controlling microglia/macrophages activation. Navarro-
Flores and Cauli  review several clinical aspects relevant for the quality of life in patients with the diabetic foot, which present
several immune and metabolic alterations (leading among others, to an increased susceptibility to infections and degenerative
changes in several tissues and organs). Different aspects related to diabetic foot syndrome such as physical alterations, psychological
complaints and even disorders, socio-economic difficulties can affect the quality of life of these patients and increased
the burden of this pathology. Ageing is characterized by a peripheral subversion of the immune system with a condition
of inflamm-ageing. Neuroinflammation and neurodegenerative diseases seem to be a central manifestation of a peripheral perturbation
of the immune machinery. Magrone et al.  reviewed the role of dietary products and nutraceuticals as a useful intervention
to lead to a down-regulation of the oxidative and pro-inflammatory profile in ageing and diseases-related to ageing
processes. Special emphasis in their review is focused on polyunsaturated fatty acids, polyphenols, micronutrients and preprobiotics
and synbiotics. Buigues et al.  published the results of a cardiovascular prevention and rehabilitation programme
(CVPRP) are an established model of care designed to improve risk factor management in patients with coronary heart disease
(CHD) in Spain. From a European multicentric study (EUROACTION). The EUROACTION nurse-led CVPRP enabled coronary
patients to control lipid profile to the European targets for cardiovascular disease prevention and rehabilitation. A large
proportion of patients were prescribed statin therapy as cardioprotective medication with favorable changes in medication for
coronary patients. The study outlined the importance of these interdisciplinary programmes for cardiovascular prevention in
CHD patients. Bodolea et al.  whether peripheral blood cell counts, and its subpopulations, red blood cell and platelets, morphology
and different ratios (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and red blood distribution width-toplatelet
ratio) are associated with frailty syndrome in patients with cardiac diseases, and through this to improve the prediction
of frailty status in patients with cardiovascular diseases. The evaluation of peripheral blood cell composition routinely measured
in clinical practice can represent a valuable, but limited indicator, to diagnose frailty syndrome and eventually, the effects
of interventions in frail patients with cardiovascular diseases.
Nowadays, heavy metals represent serious danger to human health. In fact, they are massively spread in the environment
and, therefore, the skin, the airway and the gastro-enteric systems are the most exposed organs. In the light of the above considerations,
this special issue will deal with the heavy metal-induced damage in animals and humans and also potential interventions
with nutraceuticals will be discussed.
Salimi and associates  have provided evidence on the toxic effects of nickel and raised the necessity to find out new
drugs for preventing metal-associated damage.
Martìnez-Martìnez and associates  have elucidated the role of nickel exposure in modulating dopamine release and inhibiting
glutammate N-methyl-D-aspartate receptors.
Tramontana and associates  have reviewed the issue of nickel allergy for its importance in public health with significant
personal, social and economic impact.
Gergovska and associates  have emphasized the role of nickel allergy with special reference to the skin. In fact, the morbidity
due to this metal in terms of allergic contact dermatitis outcome is constantly growing worldwide.
Filatova and Cherpak  have clarified the immunological mechanisms involved in the development of allergic contact
dermatitis under nickel exposure, emphasizing the intervention of T helper 1 and T helper 2 cells as well as the reduced functions
of T regulatory cells.
Drenovska and associates  have pointed out the important role which nickel may play in the development of autoimmune
Son  has elucidated the molecular mechanisms of nickel-induced carcinogenesis with special reference to epigenetic
changes, activation of hypoxia signaling pathways and reactive oxygen species generation.
Das and associates  have clarified the mechanisms of vitamin C protection against nickel-mediated damage in the light of
the notion that such a vitamin reduces ferric iron to ferrous iron in the duodenum, thus, competing with nickel intestinal absorption.
Magrone and associates  have focused on the impact of heavy metals with host cells (e.g., Toll-like receptor-4). In addition,
multiple damages provoked by nickel may be attenuated by nutritional intervention and, in particular, by polyphenol administration.
Type 2 diabetes mellitus (T2DM) is a major health burden affecting 415 million adults worldwide. The prevalence is continuously
increasing at a rapid pace . It is a complex metabolic disorder where both genetic and environmental factors contribute
in the pathogenesis. To expand the understanding of the pathogenic mechanisms and improving the treatment strategies,
identification of genetic variations predisposing to T2DM is important. Candidate gene approaches, genome-wide association
studies (GWAS) and sequencing techniques have been used in the identification of common, low-frequency and rare variants of
T2DM. GWAS have identified more than 100 common variants of T2DM [2-4]. Almost all of these variants regulate insulin
secretion, and only a few regulate insulin sensitivity. However, all the genetic loci identified so far account for only about 10%
of the overall heritability of T2DM. In addition, how the novel susceptible loci are correlated with the pathophysiology of the
disease remains largely unknown. Gene-environment and gene-gene interactions are likely to contribute to the missing heritability
of T2DM [5, 6]. Besides genetics, epigenetics is believed to play a role in the pathogenesis and development of T2DM.
Dysregulation of the epigenome, especially, epigenetic modification of DNA methylation, histone modification and RNAassociated
gene silencing are found to be associated with T2DM. In recent years, progress has been made in revealing T2DMassociated
genes undergoing epigenetic alterations. Evidence suggest that environmental factors can easily influence these epigenetic
markers and increase the risk of T2DM via affecting gene expressions. Additionally, it is suspected that variable drug
response in patients with T2DM is due to different levels of T2DM-associated gene expressions [7, 8]. Thus, exploration in the
pharmacogenetic and epigenetic aspects of T2DM is needed towards personalized treatment.
In this special issue of Endocrine, Metabolic & Immune Disorders-Drug Targets (EMIDDT), Ahmed et al.  represented
an update on the role of DNA methylation and protein misfolding in diabetes. Johar et al.  provided an insightful review
focusing on the molecular basis of the biomolecular changes that occur in respect to glucose homeostasis and underlying links
between pancreatic, renal and microvascular diseases in diabetes based on oxidative stress and the unfolded protein response. In
an interesting review, Tiwari et al.  summarized the emerging significance of computational biology in drug designing and
development, pertaining to identification and validation of lead molecules for the treatment of diabetes. Hossan et al.  critically
updated the epigenetic modifications including DNA methylation, posttranslational histone modifications, ATP-dependent
chromatin remodelling and non-coding RNAs related to the pathogenesis of T2DM. In another review, Khatami et al. 
critically represented the most important candidate genes of T2DM such as CAPN10, TCF7L2, PPAR-γ, IRSs, KCNJ11, WFS1
and HNF homeoboxes in order to predict the efficacy of personalized medication strategies of T2DM.
To sum up, we would like to complete this editorial by thanking Dr. Emilio Jirillo, the Editor-in-Chief, as well as Ms. Humaira
Shabbir, Senior Manager Publications, EMIDDT, along with all the contributing authors who have enthusiastically responded
to our invitations by contributing to this special issue of EMIDDT. In addition, we would like to thank all the reviewers
who evaluated the submitted manuscripts for this special issue and provided their evaluation based on novelty and scientific
contribution in the fields of genetics and epigenetics of diabetes.
Endocrine-Metabolic Disorders (EMDs) can arise due to hormonal imbalances in the organism that lead to important
changes in glycemia, cholesterol and triglyceride levels. Metabolic disorders are a major cause of illness and death worldwide.
Metabolism is the process by which the body makes energy from proteins, carbohydrates, and fats; chemically breaking these
down in the digestive system towards sugars and acids which constitute the human body's fuel for immediate use, or for storage
in body tissues such as the liver, muscles, and body fat. Metabolic disorders in the population are increasing and dramatically
affecting human health. The main etiology of metabolic disorders is heredity; an estimated 303,000 newborns die within 4
weeks of birth every year worldwide due to congenital anomalies; and 2.68 million neonatal period deaths occurred in 2015
worldwide ; a major public health issue. Metabolic disorders may also develop when certain organs, such as the liver or pancreas,
become diseased or do not function normally; obesity, diabetes, and hyperthyroidism are common examples  whose
signs and symptoms include lethargy, excessive weight gain or loss, jaundice, and seizures among them .
Diabetes and obesity are two major diseases resulting from such hormonal imbalances. The search for new targets and effective
drugs against these diseases has become the object of study for many researchers . Various areas involved in therapeutic
application of multi-target ligands have already been evaluated: including complex disorders, bacterial drug resistance,
and drug repositioning. Although in certain cases, such disorders can be approached through combined drug therapy, multitarget
ligands present clear advantages; including more predictable pharmacokinetics, better patient compliance, and reduced
risk of drug interactions. Then, what are potential applications for the use of multi target ligands in metabolic disorders? Metabolic
control analysis (or flux-balance analysis) uses a vast set of experimental data to evaluate all of the metabolic rates in the
metabolic network, (the calculations assume that the reaction rate producing a metabolite equals the reaction rate for its consumption),
and highlights key points in the metabolism where a metabolic pathology or even a parasite is present and can be
Drs Singla & Dubey  explored the α-amylase inhibitory potential of Cocos nucifera endocarp ethanolic extract. The DNS
based α-amylase assay indicated that the IC50 value for the extract was approximately 100 μg/ml. At higher doses, i.e. above
250 μg/ml, it presented greater α-amylase inhibition than the standard drug, Acarbose when tested in vitro. The ethanolic extract
of C. nucifera presented no hemolytic effects when plate tested on sheep blood agar compared to the standard sodium
lauryl sulphate. The extract’s phytochemical screening indicated high contents of alkaloids, tannins, flavonoids, saponins,
triterpenes, glycosides, carbohydrates, terpenoids, quinones and lactones. Further, GC-MS analysis (Similarity Index was >
90%) predicted myristic acid, syringaldehyde, eugenol, vanillin, 2,4-di-tert-butylphenol, lauric acid, palmitic acid methyl ester
and γ-sitosterol as the phytoconstituents most likely present in the extract. In silico docking studies were performed using VLife
MDS 4.6 software and these molecules, (predicted through the GC-MS analysis), were docked co-crystallized with (Acarbose),
tracking the active site and all other clefts of porcine pancreatic α-amylase (1OSE). γ-sitosterol presented the strongest affinity
towards the active site which was tracked by the co-crystallized ligand along with cavities 1 and 2; significant interactions were
observed at the co-crystallized active site, as well as at 1OSE cavity 4. ADMET analysis was done using StarDrop 6.4 and
Derek Nexus which provided information about the structural features influencing the ADMET properties. The correlation between
the ADME properties of the molecules together with their docking scores provided this design rationale for tailoring of
derivatives from these molecules.
Khan et al.  focused on preclinical studies of various glycosides with in vitro α-glucosidase inhibitory activity. The surveyed
literature revealed marked (extremely potent) inhibitory profiles for various glycosides relative to the standard Acarbose.
Such glycosides are strong candidates for more detailed studies that might ascertain their clinical potential to manage diabetes,
where addressing multiple targets is required.
Pseudomonas aeruginosa is one of the major pathogens associated with acute tissue damage in patients with Diabetic Foot
Ulcer (DFU). Owing to a variety of intrinsic and acquired molecular mechanisms, antibiotic resistance in P. aeruginosa often
bodes poorly for predictable and favorable clinical outcomes. In a study aimed to determine the frequency of Extended-
Spectrum β-Lactamases (ESBLs) in multi-drug resistant P. aeruginosa in diabetic foot patients, Hassan et al.  showed that P.
aeruginosa isolates present significant differences in their ESBL gene patterns. Polymxin B was found to be most effective
drug against the tested P. aeruginosa isolates and SHV-1 was most the common ESBL among the strains.
Panwar & Singh  discuss obesity, a well-known multifactor disorder facing public health authorities around the world.
Increasing rates of obesity have been characterized together with liver disease, various chronic diseases, diabetes mellitus, hypertension,
stroke, heart malfunction, reproductive and gastrointestinal diseases, and gallstones. Pancreatic lipase, an essential
enzyme involved in digestion and absorption of lipids, has become a potential drug target for developing anti-obesity therapeutics
to cure obesity.
We, the Guest-Editors, would like to express our gratitude to the many authors who contributed to this special issue, reporting
investigations in various aspects of Multi-Target Drugs Against Metabolic Disorders.
Neuropsychiatric disorders are common debilitating conditions associated with poor quality of life and
premature mortality. Several metabolic alterations are found in these disorders and many
neuropsychiatric disorders often co-occur with metabolic disturbances. The knowledge of these
alterations may offer the possibility to evaluate new pharmacological and non-pharmacological
interventions to modulate those alterations leading to an improvement of patients' life and their
environment. The thematic issue wishes to shed new lights in this exciting and insightful field of
No Text Found